

Ref: FOI/GS/ID 8033

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

09 March 2023

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to breast cancer.

You asked:

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- a. Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)*
- b. Abemaciclib + Fulvestrant*
- c. Alpelisib + Fulvestrant*
- d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent*
- e. Atezolizumab + Nab-paclitaxel/Paclitaxel*
- f. Capecitabine as a single agent*
- g. Eribulin as a single agent or in combination*
- h. Everolimus + Exemestane*
- i. Fulvestrant as a single agent*
- j. Lapatinib*
- k. Neratinib*
- l. Parp Inhibitors (Olaparib/Talazoparib)*
- m. Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)*
- n. Palbociclib + Fulvestrant*
- o. Pembrolizumab*
- p. Platinum (e.g. carboplatin or cisplatin) as a single agent*
- q. Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)*
- r. Ribociclib + Fulvestrant*
- s. Sacituzumab Govitecan*
- t. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent*
- u. Taxane and/or Anthracycline in combination*

- v. *Trastuzumab as a single agent or in combination*
- w. *Trastuzumab emtansine*
- x. *Transtuzumab deruxtecan*
- y. *Any other active systemic anti-cancer therapy*

Q2. *Of the patients treated for breast cancer with Abemaciclib + Aromatase Inhibitor in the past the 3 months, please provide the number of patients with:*

- a. *early/locally advanced breast cancer (Stages 1 to 3B)*
- b. *advanced/metastatic breast cancer (Stages 3C and 4)*

Trust response:

Answers below are for the period 1/11/2022-31/1/2023.

Q1

- a. 11
- b. 3
- c. 0
- d. 0
- e. 6
- f. 31
- g. 4
- h. 3
- i. 1
- j. 0
- k. 0
- l. 0
- m. 73
- n. 25
- o. 0
- p. 0
- q. 8
- r. 0
- s. 3
- t. 14
- u. 70
- v. 91
- w. 14
- x. 2
- y. 2

Q2

- a. 8
- b. 3